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ABSTRACT
Increased plasma triglycerides concentrations are an independent risk factor for
cardiovascular disease.  Numerous studies support a reproducible genetic association
between two minor haplotypes in the human apolipoprotein A5 gene (APOA5) and
increased plasma triglyceride concentrations.  We thus sought to investigate the effect of
these minor haplotypes (APOA5*2 and APOA5*3) on ApoAV plasma levels through the
precise insertion of single-copy intact APOA5 haplotypes at a targeted location in the
mouse genome.  While we found no difference in the amount of human plasma ApoAV
in mice containing the common APOA5*1  and minor APOA5*2 haplotype, the
introduction of the single APOA5*3 defining allele (19W) resulted in 3-fold lower
ApoAV plasma levels consistent with existing genetic association studies.  These results
indicate that S19W polymorphism is likely to be functional and explain the strong
association of this variant with plasma triglycerides supporting the value of sensitive in
vivo assays to define the functional nature of human haplotypes.
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INTRODUCTION
Elevated lipid plasma levels are a significant risk factor for stroke and coronary artery
disease [1, 2].  The apolipoprotein gene cluster (APOA5/APOA4/APOC3/APOA1) on
human chromosome 11 (Fig. 1a) is one locus that has been genetically linked to inter-
individuals differences in plasma lipid levels [3, 4].  Specifically, APOA5 is one member
of this cluster that has been strongly implicated in influencing plasma triglyceride levels
in both mice and humans [5].  Mice lacking apoa5 have increased plasma concentrations,
while mice over-expressing human APOA5 exhibit decreased plasma triglyceride
concentrations [5].  In humans, numerous studies in several different ethnic populations
have shown significant association between two minor APOA5 haplotypes, APOA5*2
and APOA5*3, and elevated plasma triglyceride levels [5-12].  It is estimated that 53% of
Hispanics, 35% of African-Americans, and 24% of Caucasians carry at least one of these
two minor haplotypes [6], thus suggesting these haplotypes may be a common risk factor
for atherosclerosis in humans.
Recent in vitro studies have provided initial clues to the possible functional alleles within
these minor APOA5 haplotypes.  In humans, genetic studies showed that carriers of the
minor APOA5*2 haplotype [defined by the following nucleotide changes -1131T>C
(rs662799), -3A>G (rs651821), 751G>T (rs2072560), and 1891T>C (rs2266788)]
displayed significantly lower ApoAV levels compared to the common -1131T variant
(152.4 ng/ml versus 200.8 ng/ml) as well as elevated triglyceride levels (1.46 mmol/l
versus 0.88 mmol/l)[13].  However, subsequent in vitro functional studies of -1131C and
other APOA5*2 variants yielded no significant alteration in transcription or translation in
cell lines [14].  One possible explanation for this observation is based on the strong
linkage disequilibrium of the APOA5*2 haplotype with three neighboring APOC3
variants [15] (-482C>T, -455T>C, and 3238G>C) that have been repeatedly associated
with elevated plasma triglyceride concentrations in several human populations [7, 16-30].
Based on all these results, it remains unclear whether the APOA5*2 haplotype contributes
to elevated plasma triglycerides through a cooperative effect of all four APOA5 variants
or in association with linked causal APOC3 variants.
In contrast, the APOA5*3 haplotype associated with elevated triglyceride concentrations
is defined by a single coding variant allele [c56G (rs3135506), changing 19S to 19W]
and in vitro studies revealed a functional consequence of this resulting amino acid
substitution [14].  Specifically, molecular modeling of the W19 variant predicted reduced
translocation across the endoplasmic reticulum, which was functionally supported
through in vitro studies indicating a two-fold reduction in protein secretion in comparison
to the common 19S allele at this position [14].  In addition, unlike APOA5*2, APOA5*3
showed no association with any neighboring APOC3 SNP allele [15], suggesting that it is
an isolated genetic variant that is functionally responsible for the APOA5*3 haplotype
association with elevated triglyceride levels.
To further assess whether minor human APOA5 haplotypes by themselves result in
altered ApoAV plasma levels in vivo, we inserted APOA5 haplotype constructs into mice
through targeted embryonic stem (ES) cell engineering.  To circumvent the standard
mouse transgenic complications of variation in copy number and integration sites, we
inserted each haplotype construct into a vector designed to rescue an ES cell harboring a
partially defective hypoxanthine phosphoribosyltransferase gene (hprt), thereby allowing
for appropriately targeted colonies to be positively selected using Hypoxanthine
Aminopterin Thymidine (HAT) medium [31].  Through these studies, we find that while
APOA5*2 failed to result in any considerable change in ApoAV plasma levels compared
to APOA5*1, introduction of the W19 variant into the minor APOA5*2 haplotype
significantly reduced ApoAV plasma levels in vivo.
RESULTS
Generation of APOA5 Haplotype Mouse Lines
To generate each APOA5 haplotype construct, we electronically identified 2 publicly
available bacterial artificial chromosome (BAC) clones that corresponded to haplotypes
APOA5*1 (BAC CTC-270C21) and APOA5*2 (BAC RP11-442E11).  From these BACs,
we cloned an 11,360 bp fragment (chr11:116,163,727-116,175,086; hg18) that
corresponds to the human APOA5 region (Fig. 1b; see Methods).  The minor APOA5*3
haplotype was then constructed through site-directed mutagenesis of the cloned
APOA5*1 haplotype, creating a single change of c56C to c56G (a.k.a. S19 to 19W).  In
addition, to ascertain the consequence of the 19W change we generated a fourth hybrid
haplotype of APOA5*2 and APOA5*3 through similar site-directed mutagenesis of
cloned haplotype APOA5*2, changing c56C to c56G, hereon referred to as APOA*4 (Fig.
1c).
All four haplotypes were cloned into an hprt replacement vector [31] and each construct
was independently electroporated into a previously described E14TG2a hprt-deficient
129 ES cell line (Fig. 1d) (see methods) [32].  Colonies resistant to HAT medium were
screened using PCR and Southern analysis (data not shown) and were subsequently
injected into C57BL/6J blastocyst stage embryos.  The resulting male chimeras were bred
to C57BL/6J females to allow for detection of ES cell transmission based on the 129
strain cell line derived agouti coat color marker.  Female agouti mice positive for the
transgene were bred to C57BL/6J males to generate transgene positive hemizygous males
(hprt is located on the X-chromosome).  While haplotypes APOA5*1, APOA5*2, and
APOA5*4 were successfully transmitted through the germline, none of the resulting
chimeric mice from two separate APOA5*3 ES clones did so, despite repeated attempts.
We thus limited our analysis to aforementioned mouse lines.
Plasma ApoAV levels are reduced for Haplotype APOA5*4 but not APOA5*2 Mouse
Lines
To date, APOA5 expression has only been detected in the liver where it is thought to be
secreted into the plasma, functioning in increasing lipolysis in the periphery as well as
LDL clearance by the liver.  We thus sought to determine if ApoAV plasma levels were
altered due to the allelic variants found within their respective haplotypes.  We measured
human ApoAV plasma levels in male mice using a human-specific ApoAV antibody.  As
a control, we found no detectable levels of human ApoAV in littermates that were
negative for the transgene (n=18).  In contrast, we detected an average ApoAV plasma
level of 0.628 mg/dL in transgenic mice for the most common human APOA5*1
haplotype (Fig. 2a).  It is worth noting that these levels are considerably lower than the
average human levels that are estimated to be 17.92 ± 7.48 mg/dL [13].  We next
determined if the minor APOA5 haplotypes associated with increased triglyceride levels
in humans displayed altered ApoAV plasma levels compared to APOA5*1.  No
significant difference (0.628 versus 0.593mg/dL; p=0.810, t-test) was observed between
APOA5*1 and APOA5*2 transgenic mice.  In contrast, APOA5*4 which contains a single
S19 to W19 change within APOA5*2, showed significantly lower ApoAV plasma levels
compared to APOA5*1 (0.173 versus 0.628 mg/dL; p=0.002, t-test) (Fig. 2a).  Combined,
these results indicate that while the APOA5*2 variants do not have a significant effect on
ApoAV plasma levels, the W19 allele alone resulted in substantially lower ApoAV
levels.
Finally, we measured triglyceride levels in mice derived from all APOA5 haplotype lines
observing no differences between these cohorts (Fig. 2b).  This was not unexpected since
the endogenous mouse locus for apoa5 remains intact within these hprt-based targeted
mice.  Future studies aimed at determining the effects of these transgenes with apoa5-
deficient mice would directly assess the ability of these haplotypes to recapitulate the
triglyceride phenotypic difference found in humans.  Nevertheless, the established role of
decreased ApoAV function leading to increased triglycerides in knockout mice, is
consistent with human APOA5 minor haplotypes leading to lower ApoAV protein levels
which in turn raise triglycerides in plasma.
DISCUSSION
Our goal in this study was to determine the in vivo effect of APOA5 polymorphisms
repeatedly associated with inter-individual differences in plasma triglyceride
concentrations.  Using an hprt mouse targeting scheme, we created male mice each
carrying a different single copy of a human APOA5 haplotype.  We were thus able to
avoid the complexities of regular transgenic mice where multiple copies and different
insertion sites can significantly effect the expression of a transgene.  In addition, this
transgenic scheme enabled the disconnection of APOA5 from the neighboring APOC3 (as
well as APOA4 and APOA1), consequently revealing that only one of the two minor
haplotypes associated with increase triglycerides in humans appear causative of this
plasma phenotypic difference across humans.
Previous in vitro functional studies on the majority of variants defining APOA5*2 have
suggested that the variants within this haplotype are not functional [14].  However, these
studies were conducted within cell lines and were not able to assess all haplotype
defining alleles in combination; but rather studied each independently based on
predictions on how they may alter gene function.  By inserting the entire APOA5*2
haplotype into the mouse, we find that these alleles combined do not have a cooperative
effect that might otherwise support their causal role to the observed human genetic
association with increased triglycerides.  These findings further suggest this APOA5*2
haplotype association may be explained due to its strong linkage disequilibrium with
previously characterized triglyceride elevating APOC3 alleles.  It will be interesting in
future studies to determine the effect of APOC3  minor haplotypes associated with
increase triglycerides through similar in vivo studies.
We can strongly infer that the S19W variant is functional.  This is based on the
observation that the single change of APOA5*2 haplotype S19 to W19 resulted in a three-
fold decrease in ApoAV plasma levels in vivo.  This decrease is consistent with previous
functional studies that correlate this change with a significant reduction in ApoAV
secretion levels in vitro [14].  The phenotypic outcome of such a reduction, elevated
plasma triglyceride levels, can be inferred from apoa5 mouse knockout mice.  Apoa5 null
homozygous mice have four times as much plasma triglyceride levels as their wild-type
littermates[5], thus indicating that the expected phenotype of lower ApoAV would be
higher plasma triglyceride levels.  In conclusion, these results further support individuals
carrying the APOA5*3 haplotype have a higher risk for elevated plasma triglyceride
levels directly through the S19W genetic variant that defines this haplotype.
While this study was focused on APOA5 specific haplotypes, the results are relevant to
the increasing number of genetic associations being identified in humans.  These
statistical associations gain power through validation in independent cohorts, but
ultimately lack formal proof of their causative nature.  Through a combination of in vitro
and in vivo studies as described here it is anticipated that haplotypes can be functionally
linked to their associated human phenotypes and provide an experimental means to define
the ultimate functional allele(s) within these stretches of human DNA.
MATERIALS AND METHODS
Cloning the APOA5 hprt constructs
BACs 270C21 (APOA*1; GenBank AP001481) and 442e11 (APOA*2; GenBank
AC007707) were restriction digested sequentially with Not I and BstE II and separated on
a pulse field gel without ethidium bromide.  Electronically predicted 11.5 kb fragments
were gel excised and purified using QiaEx II kit (Qiagen, Valencia, CA), blunt-end
repaired using EpiCenter CopyControl PCR Cloning kit (Epicentre Madison, WI), and
ligated into a pCCI vector (Epicentre Madison, WI).  5kb Hind III fragments from both
the APOA5*1 and APOA5*2 clones in pCCI were cloned into a pBS vector (Invitrogen)
to facilitate the ease of site-directed mutagenesis.  In both vectors site-directed
mutagenesis of the APOA5*3 variant (c56C>G) was carried out using Quickchange site-
directed mutagenesis kit (Stratgene}. After mutagenesis clones was re-verified by
sequencing with primers F1-AGAGGCCTCAGCTTTTCCAGGA, R1-
GCGGATCCGAGCAGAGCAGA, R2-GCGGATCCGAGCAGAGCAGG, R3-
TCTGGCTCTTCTTTCAGCGTTTTC, and R4-TCTGGCTCTTCTTTCAGCGTTTTG.
Next, 5kb Hind III fragments were gel excised from pBS and ligated back into the pCCI
thus generating haplotypes APOA5*3 and APOA5*4.  We then cloned these sequences
into the pMP8NEB delta lacZ vector[31] (a kind gift from Sarah K. Bronson) using Not I.
To verify there were no mistakes in orientation and nucleotide sequence of APOA5 and
the haplotype determining alleles, we analyzed these vectors using restriction enzyme
based analysis and sequencing.
hprt targeting
All 4 APOA5 haplotypes within the pMP8NEB delta lacZ vectors were linearized with
Not I restriction enzyme and electroporated into a E14TG2a hprt-deficient 129 ES cell
line[32]. Cells were grown on murine embryonic fibroblast in in DMEM (Gibco)
supplemented with 10% fetal bovine serum (Hyclone), L-Glutamine (Gibco), non-
essential amino acids (Gibco), HEPES (Gibco) Beta-mercaptoethanol (Sigma),
penicillin/streptomycin (Gibco) and ESGRO ( Chemicon).  Positive colonies were
selected for using HAT medium and were screened by PCR using primers that spanned
the mouse hprt gene and human AV gene junction.  Sequence for primers are: mHPRT F
5 ’ T G A G T T C C T G C A T T G A G C A A C T G A 3 ’  a n d  h A p o A V  R
5’TGAGATGCAGAGGGGACACTTGG 3’. For Southern blot 10 µg of genomic DNA
was digested with Sca I and the probe was synthesized using the following PCR primer
p a i r :   5 ’  T T A T G G T A C T G G C A G G G A G A T T A G G 3 ’  a n d
5’CAGAACATCTTGAAACCCAGCATCC 3’.  The resultant male chimeras were bred
to C57BL/6J females, and heterozygous females generated from these crosses were
mated with C57BL/6J males to generate transgene positive hemizygous males.
Triglyceride measurements
All animals were fed standard chow diet and were analyzed between 2 to 4 months of
age.  Blood samples were collected after a 5-hour fast by retro-orbital bleeding using
heparinized microhematocrit tubes.  Total triglyceride concentrations were measured
using enzymatic methods (Sigma 337-A) in 96 well plates using a Spectramax 250
(Molecular Devices).
APOA5 measurements
A pool of two monoclonal anti-human apoAV antibodies, raised in mice by using
recombinant protein, was used at 10 µg/ml in PBS 0.1M pH 7.2 to coat the wells of the
microtiter plates at room temperature overnight.  The wells were washed twice with PBS
0.1M and then saturated with 3% BSA/PBS for 1h at 37°C.  For quantitation, a pool of
human plasma was calibrated and titrated using apoAV recombinant protein as a primary
standard.  Then, the pool of plasma was used for the calibration curve.  All dilutions were
done in the blocking buffer (1% BSA/PBS). One hundred microliters of the antigen
solution was added to the wells and incubated for 2h at room temperature.  The wells
were washed four times with PBS followed by an addition of an anti-apoAV polyclonal
antibody (1:400), produced in goat using synthetic peptide, and incubated for 2h at 37°C.
Unbound antibody was removed by washing four times, and 100 µl of goat anti-rabbit
IgG-biotin conjugate diluted (1:20000; Sigma) was added to each well.  The plates were
incubated for 1h at 37°C and washed several times.  Following incubation with the
biotinylated antibody, a solution of streptavidin-alkaline phosphatase (1:500; Sigma) was
added for 30 min at 37°C.  Then, detection using p-nitropheny phosphate substrate
(pNPP; Sigma) was performed in the dark at room temperature and the absorbance at 405
nm was measured using a microplate photometer (Dynex Technologies).
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FIGURE LEGENDS
Figure 1: Generation of APOA5 haplotype mouse lines. A) Apolipoprotein gene cluster
on human chromosome 11. B) APOA5 gene and location of haplotype determining
variants. C) APOA5 haplotype constructs D) Recombination of the APOA5 haplotype
constructs into a defective hprt locus in the mouse.
Figure 2: ApoAV and triglyceride plasma levels in APOA5 haplotype mice. A) ApoAV
plasma levels. B) Triglyceride plasma levels.  Error bars indicate the standard error, ‘N’
below the chart indicates the number of mice assayed, followed by the mean ApoAV or
triglyceride plasma levels (mg/dL) and the standard error in each experiment.
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